Vision Capital Management’s Pfizer PFE Stock Holding History

Vision Capital Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,552	Closed	-$210K	–	108
2021 Q4	$210K	Buy	+3,552	New	+$176K	0.03%	110
2020 Q1	–	Sell	-7,962	Closed	-$296K	–	98
2019 Q4	$296K	Buy	+7,962	New	+$284K	0.07%	81

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Vision Capital Management's PFE Position: Q1 2022 in Review

Vision Capital Management sold out of Pfizer (PFE) in Q1 2022, closing a stake of 3,552 shares — an estimated $210K sold.

Vision Capital Management first reported a position in PFE in Q4 2019 and held it in 2 quarters. The position peaked at $296K in Q4 2019. 3,195 funds tracked by Wall St. Rank hold PFE as of Q1 2022.

Vision Capital Management reported no remaining Pfizer position as of Q1 2022 after selling out during the quarter.
Vision Capital Management sold 3,552 Pfizer shares in Q1 2022, an estimated $210K.
Vision Capital Management first reported a position in Pfizer in Q4 2019 and held it in 2 quarters.
Vision Capital Management's Pfizer position peaked at $296K in Q4 2019.
3,195 funds tracked by Wall St. Rank held Pfizer as of Q1 2022.

Based on Vision Capital Management's 13F filing for Q1 2022, filed 28 Apr 2022.